Safety of Terbogrel in Patients With Primary Pulmonary Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

1998-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to assess the safety of terbogrel during open-label, long-term treatment in medically stable or improving patients with primary pulmonary hypertension who have completed the 12-week, double-blind randomized trial of terbogrel (protocol 528.19)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension

NCT02223481

Hypertension, Pulmonary

COMPLETED PHASE2

TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

NCT07223528

Pulmonary Hypertension

NOT_YET_RECRUITING PHASE1/PHASE2

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742

Pulmonary Arterial Hypertension

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Medication Reconciliation in Pulmonary Hypertension

NCT04744584

Pulmonary Hypertension Pulmonary Hypertension Chronic Thromboembolic Pulmonary Arterial Hypertension

COMPLETED

Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

NCT00352430

Pulmonary Hypertension

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension, Pulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Terbogrel

Group Type EXPERIMENTAL

Terbogrel

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Terbogrel

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients who

* completed the preceding primary pulmonary hypertension, double-blinded clinical trial of terbogrel (protocol 528.19)
* provide informed consent to participate in this trial
* are in a stable or improving medical condition, in the opinion of the investigator
* enter the study immediately upon their completion of the preceding double-blind Trial 528.19, or enter the study within one month of completing the preceding trial as long as their medical condition has remained stable or continues to improve in the interim

Exclusion Criteria

* Development of an unstable medical condition during or following completion of the preceding clinical trial which, in the investigator's opinion, may be worsened by treatment with terbogrel
* Premature discontinuation of the preceding terbogrel clinical trial due to an adverse event or for any other reason
* Pregnant or nursing women, or women of childbearing potential (less than one year postmenopausal or not surgically sterilized) who are not using adequate methods of birth control

Eligible Sex

ALL

Accepts Healthy Volunteers

No